Systemic availability of itraconazole in lung transplantation

Thomas F. Patterson, Jay Peters, Stephanie M. Levine, Antonio Anzueto, Charles L. Bryan, Edward Y. Sako, O. Lawayne Miller, John H. Calhoon, Michael G. Rinaldi

Research output: Contribution to journalArticle

44 Scopus citations

Abstract

Systemic availability of itraconazole in lung transplantation was evaluated by serially measuring the bioactivity of itraconazole in lung transplant patients who received itraconazole for prophylaxis (n = 12) or therapy (n = 5). These patients also received concomitant antacid and H2 blocker therapy. In patients receiving itraconazole at 200 and 400 mg/day, the median concentrations in serum were 0.5 μg/ml (range, <0.5 to 2.7) and 3.5 mg/ml (<0.5 to 14), respectively. The concentration following administration of 400 mg/day was >2.5 μg/ml in 56% of samples, while only 4% of samples from patients who were administered 200 mg/day had levels over 2.5 μg/ml. This study documents that itraconazole can be absorbed in patients receiving concomitant antacid and H2 blocker therapy. However, the reduced and variable absorption suggests the importance of confirming drug delivery by measurement of concentrations in serum.

Original languageEnglish (US)
Pages (from-to)2217-2220
Number of pages4
JournalAntimicrobial agents and chemotherapy
Volume40
Issue number9
DOIs
StatePublished - Sep 1996

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Systemic availability of itraconazole in lung transplantation'. Together they form a unique fingerprint.

Cite this